Solventum (NYSE: SOLV) has acquired an FDA clearance for a new combination of two of its active wound care approaches, which the company said will help streamline the healing process.
Huntington’s disease is caused by repetitive “stutters” in DNA—specifically repeated CAG sequences—that expand abnormally over time, leading to toxic protein accumulation that contributes to the progression of the disease. There is currently no cure for this rare and fatal genetic disease.
The Teleflex (NYSE: TFX) Freesolve RMS (resorbable magnesium scaffold) has won FDA Breakthrough Device designation for percutaneous coronary intervention (PCI).
Most people remember the sharp sting of removing a bandage from the knee. For people with fragile skin, however, this moment can be more than brief discomfort. In neonates, older adults and critically ill patients, repeated attachment and removal of medical adhesives can cause irritation, epidermal damage and even skin stripping.
UCLA investigators have developed a new artificial intelligence-based platform that could help scientists identify promising drug combinations to overcome treatment resistance in cancer.
Unresponsive ICU patients in a new Columbia study were able to raise and lower the frequency of a beeping tone with their minds, via noninvasive EEG electrodes that recorded and translated their brain waves.
A needle-free vaccination method protected mice against the viruses that cause COVID-19 and flu, offering a possible new way to deliver mRNA vaccines while limiting unwanted inflammation.
Anatomy segmentation and three-dimensional skeletal visualization arrive with this clearance; an injury detection module for clinical decision support is in development on the platform roadmap
Clearance is supported by BOLT-DVT findings on clot removal, safety and patient outcomes
Edwards Lifesciences (NYSE: EW) obtained FDA approval for its minimally invasive procedure to help repair a leaky tricuspid heart valve.